Ichnos Sciences Inc. today announced dosing of the first patient in the Phase 1 first-in-human clinical trial of ISB 2001, a BCMA x CD38 x CD3 TREAT™ trispecific antibody1, for the treatment of multiple myeloma.
Ichnos Sciences Inc. today announced dosing of the first patient in the Phase 1 first-in-human clinical trial of ISB 2001, a BCMA x CD38 x CD3 TREAT™ trispecific antibody1, for the treatment of multiple myeloma.